ACLS vs BRZE
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ACLS exhibits strong financial health per the Piotroski F-Score of 7/9, indicating robust operational efficiency and stability, though the absence of an Altman Z-Score raises caution regarding default risk. The stock trades at a premium to its Graham Number ($53.67) and intrinsic value ($26.60), suggesting valuation is driven by growth expectations rather than conservative fundamentals. Despite a recent earnings decline (YoY EPS -28.3%), the company has consistently beaten estimates over the past four quarters with an average surprise of 37.69%, signaling strong earnings quality. However, negative revenue and earnings growth, combined with bearish insider activity, introduce near-term caution. The 1-year return of +43% reflects strong momentum, but recent 6-month and 1-month declines suggest profit-taking or sector rotation.
BRZE shows neutral fundamentals based on deterministic rules. Financial strength is stable (F-Score 5/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ACLS vs BRZE: Head-to-Head Comparison
This page compares Axcelis Technologies, Inc. (ACLS) and Braze, Inc. (BRZE) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.